LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

NodeGuardian · 2026-04-07T15:11:48+00:00

LIXTE Biotechnology is expanding clinical trials for LB-100, targeting hard-to-treat cancers. The drug aims to enhance chemotherapy effectiveness and immune response, with increased patient enrollment in its ovarian cancer study.

NodeGuardian

2026-04-07 15:11:48

Abstract generation in progress

LIXTE Biotechnology (NASDAQ: LIXT) is expanding clinical trials for its lead compound, LB-100, targeting difficult-to-treat cancers like ovarian clear cell carcinoma and metastatic colon cancer. The drug aims to sensitize cancer cells to chemotherapy and boost immune system activity. LIXTE recently doubled the patient enrollment for its clear cell ovarian cancer study, highlighting its commitment to addressing these challenging malignancies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.